



## REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference

June 1, 2023 11:05 AM EDT

ROCKVILLE, Md., June 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present and host one-on-one investor meetings at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023.

### Jefferies Global Healthcare Conference

**Date:** Thursday, June 8, 2023

**Presentation:** 1:30 p.m. ET

A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

### About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

### Contacts:

Investors:

Chris Brinzey

ICR Westwicke

339-970-2843

[chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-jefferies-global-healthcare-conference-301839716.html>

SOURCE REGENXBIO Inc.